Predictors and Biomarkers of Treatment Gains in a Clinical Stroke Trial Targeting the Lower Extremity
BACKGROUND AND PURPOSE—Behavioral measures are often used to distinguish subgroups of patients with stroke (eg, to predict treatment gains, stratify clinical trial enrollees, or select rehabilitation therapy). In studies of the upper extremity, measures of brain function using functional magnetic re...
Gespeichert in:
Veröffentlicht in: | Stroke (1970) 2014-08, Vol.45 (8), p.2379-2384 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2384 |
---|---|
container_issue | 8 |
container_start_page | 2379 |
container_title | Stroke (1970) |
container_volume | 45 |
creator | Burke, Erin Dobkin, Bruce H Noser, Elizabeth A Enney, Lori A Cramer, Steven C |
description | BACKGROUND AND PURPOSE—Behavioral measures are often used to distinguish subgroups of patients with stroke (eg, to predict treatment gains, stratify clinical trial enrollees, or select rehabilitation therapy). In studies of the upper extremity, measures of brain function using functional magnetic resonance imaging (fMRI) have also been found useful, but this approach has not been examined for the lower extremity. The current study hypothesized that an fMRI-based measure of cortical function would significantly improve prediction of treatment-induced lower extremity behavioral gains. Biomarkers of treatment gains were also explored.
METHODS—Patients with hemiparesis 1 to 12 months after stroke were enrolled in a double-blind, placebo-controlled, randomized clinical trial of ropinirole+physical therapy versus placebo+physical therapy, results of which have previously been reported (NCT00221390). Primary end point was change in gait velocity. Enrollees underwent baseline multimodal assessment that included 19 measures spanning 5 assessment categories (medical history, impairment, disability, brain injury, and brain function), and also underwent reassessment 3 weeks after end of therapy.
RESULTS—In bivariate analysis, 8 baseline measures belonging to 4 categories (medical history, impairment, disability, and brain function) significantly predicted change in gait velocity. Prediction was strongest, however, using a multivariate model containing 2 measures (leg Fugl–Meyer score and fMRI activation volume within ipsilesional foot sensorimotor cortex). Increased activation volume within bilateral foot primary sensorimotor cortex correlated positively with treatment-induced leg motor gains.
CONCLUSIONS—A multimodal model incorporating behavioral and fMRI measures best predicted treatment-induced changes in gait velocity in a clinical trial setting. Results also suggest potential use of fMRI measures as biomarkers of treatment gains. |
doi_str_mv | 10.1161/STROKEAHA.114.005436 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4129459</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1549632038</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6236-7e5c7b99d25892ddbf08c0a3aa5b542c889a48f0f1d63ae2cd3c84a45a76c9183</originalsourceid><addsrcrecordid>eNp9kU9vEzEQxS0EomnhGyDkCxKXLf67a1-QQhRaRKQiGs7WxOtNTHbXxXYo_fZ1lBDgwsl68m9m3sxD6BUll5TW9N3t8uvN5_n0elqkuCRECl4_QRMqmahEzdRTNCGE64oJrc_QeUrfCSGMK_kcnTFJGqJrOkHuS3SttznEhGFs8QcfBohbV2To8DI6yIMbM74CPybsRwx41vvRW-jxbY5h6wrki1hCXLvsxzXOG4cX4d5FPP-Voxt8fniBnnXQJ_fy-F6gbx_ny9l1tbi5-jSbLipbM15XjZO2WWndMqk0a9tVR5QlwAHkSgpmldIgVEc62tYcHLMtt0qAkNDUVlPFL9D7Q9-73WpwrS3OI_TmLvqy1IMJ4M2_P6PfmHX4aQRlWkhdGrw9Nojhx86lbAafrOt7GF3YJUOl0DVnhO9niQNqY0gpuu40hhKzT8icEipSmENCpez13xZPRb8jKcCbIwCpXLmLMFqf_nCqIYKovVV14O5Dn0te235Xbm42Dvq8-b-HR8ORrdQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1549632038</pqid></control><display><type>article</type><title>Predictors and Biomarkers of Treatment Gains in a Clinical Stroke Trial Targeting the Lower Extremity</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><source>Alma/SFX Local Collection</source><creator>Burke, Erin ; Dobkin, Bruce H ; Noser, Elizabeth A ; Enney, Lori A ; Cramer, Steven C</creator><creatorcontrib>Burke, Erin ; Dobkin, Bruce H ; Noser, Elizabeth A ; Enney, Lori A ; Cramer, Steven C</creatorcontrib><description>BACKGROUND AND PURPOSE—Behavioral measures are often used to distinguish subgroups of patients with stroke (eg, to predict treatment gains, stratify clinical trial enrollees, or select rehabilitation therapy). In studies of the upper extremity, measures of brain function using functional magnetic resonance imaging (fMRI) have also been found useful, but this approach has not been examined for the lower extremity. The current study hypothesized that an fMRI-based measure of cortical function would significantly improve prediction of treatment-induced lower extremity behavioral gains. Biomarkers of treatment gains were also explored.
METHODS—Patients with hemiparesis 1 to 12 months after stroke were enrolled in a double-blind, placebo-controlled, randomized clinical trial of ropinirole+physical therapy versus placebo+physical therapy, results of which have previously been reported (NCT00221390). Primary end point was change in gait velocity. Enrollees underwent baseline multimodal assessment that included 19 measures spanning 5 assessment categories (medical history, impairment, disability, brain injury, and brain function), and also underwent reassessment 3 weeks after end of therapy.
RESULTS—In bivariate analysis, 8 baseline measures belonging to 4 categories (medical history, impairment, disability, and brain function) significantly predicted change in gait velocity. Prediction was strongest, however, using a multivariate model containing 2 measures (leg Fugl–Meyer score and fMRI activation volume within ipsilesional foot sensorimotor cortex). Increased activation volume within bilateral foot primary sensorimotor cortex correlated positively with treatment-induced leg motor gains.
CONCLUSIONS—A multimodal model incorporating behavioral and fMRI measures best predicted treatment-induced changes in gait velocity in a clinical trial setting. Results also suggest potential use of fMRI measures as biomarkers of treatment gains.</description><identifier>ISSN: 0039-2499</identifier><identifier>EISSN: 1524-4628</identifier><identifier>DOI: 10.1161/STROKEAHA.114.005436</identifier><identifier>PMID: 25070961</identifier><identifier>CODEN: SJCCA7</identifier><language>eng</language><publisher>Hagerstown, MD: American Heart Association, Inc</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Cardiovascular system ; Cerebral Cortex - physiopathology ; Combined Modality Therapy ; Double-Blind Method ; Female ; Gait - physiology ; Humans ; Indoles - therapeutic use ; Lower Extremity - physiopathology ; Magnetic Resonance Imaging ; Male ; Medical sciences ; Middle Aged ; Neurology ; Paresis - etiology ; Paresis - physiopathology ; Paresis - rehabilitation ; Pharmacology. Drug treatments ; Stroke - complications ; Stroke - physiopathology ; Stroke Rehabilitation ; Treatment Outcome ; Vascular diseases and vascular malformations of the nervous system ; Vasodilator agents. Cerebral vasodilators</subject><ispartof>Stroke (1970), 2014-08, Vol.45 (8), p.2379-2384</ispartof><rights>2014 American Heart Association, Inc.</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c6236-7e5c7b99d25892ddbf08c0a3aa5b542c889a48f0f1d63ae2cd3c84a45a76c9183</citedby><cites>FETCH-LOGICAL-c6236-7e5c7b99d25892ddbf08c0a3aa5b542c889a48f0f1d63ae2cd3c84a45a76c9183</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,882,3674,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28704089$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25070961$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Burke, Erin</creatorcontrib><creatorcontrib>Dobkin, Bruce H</creatorcontrib><creatorcontrib>Noser, Elizabeth A</creatorcontrib><creatorcontrib>Enney, Lori A</creatorcontrib><creatorcontrib>Cramer, Steven C</creatorcontrib><title>Predictors and Biomarkers of Treatment Gains in a Clinical Stroke Trial Targeting the Lower Extremity</title><title>Stroke (1970)</title><addtitle>Stroke</addtitle><description>BACKGROUND AND PURPOSE—Behavioral measures are often used to distinguish subgroups of patients with stroke (eg, to predict treatment gains, stratify clinical trial enrollees, or select rehabilitation therapy). In studies of the upper extremity, measures of brain function using functional magnetic resonance imaging (fMRI) have also been found useful, but this approach has not been examined for the lower extremity. The current study hypothesized that an fMRI-based measure of cortical function would significantly improve prediction of treatment-induced lower extremity behavioral gains. Biomarkers of treatment gains were also explored.
METHODS—Patients with hemiparesis 1 to 12 months after stroke were enrolled in a double-blind, placebo-controlled, randomized clinical trial of ropinirole+physical therapy versus placebo+physical therapy, results of which have previously been reported (NCT00221390). Primary end point was change in gait velocity. Enrollees underwent baseline multimodal assessment that included 19 measures spanning 5 assessment categories (medical history, impairment, disability, brain injury, and brain function), and also underwent reassessment 3 weeks after end of therapy.
RESULTS—In bivariate analysis, 8 baseline measures belonging to 4 categories (medical history, impairment, disability, and brain function) significantly predicted change in gait velocity. Prediction was strongest, however, using a multivariate model containing 2 measures (leg Fugl–Meyer score and fMRI activation volume within ipsilesional foot sensorimotor cortex). Increased activation volume within bilateral foot primary sensorimotor cortex correlated positively with treatment-induced leg motor gains.
CONCLUSIONS—A multimodal model incorporating behavioral and fMRI measures best predicted treatment-induced changes in gait velocity in a clinical trial setting. Results also suggest potential use of fMRI measures as biomarkers of treatment gains.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular system</subject><subject>Cerebral Cortex - physiopathology</subject><subject>Combined Modality Therapy</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Gait - physiology</subject><subject>Humans</subject><subject>Indoles - therapeutic use</subject><subject>Lower Extremity - physiopathology</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neurology</subject><subject>Paresis - etiology</subject><subject>Paresis - physiopathology</subject><subject>Paresis - rehabilitation</subject><subject>Pharmacology. Drug treatments</subject><subject>Stroke - complications</subject><subject>Stroke - physiopathology</subject><subject>Stroke Rehabilitation</subject><subject>Treatment Outcome</subject><subject>Vascular diseases and vascular malformations of the nervous system</subject><subject>Vasodilator agents. Cerebral vasodilators</subject><issn>0039-2499</issn><issn>1524-4628</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9vEzEQxS0EomnhGyDkCxKXLf67a1-QQhRaRKQiGs7WxOtNTHbXxXYo_fZ1lBDgwsl68m9m3sxD6BUll5TW9N3t8uvN5_n0elqkuCRECl4_QRMqmahEzdRTNCGE64oJrc_QeUrfCSGMK_kcnTFJGqJrOkHuS3SttznEhGFs8QcfBohbV2To8DI6yIMbM74CPybsRwx41vvRW-jxbY5h6wrki1hCXLvsxzXOG4cX4d5FPP-Voxt8fniBnnXQJ_fy-F6gbx_ny9l1tbi5-jSbLipbM15XjZO2WWndMqk0a9tVR5QlwAHkSgpmldIgVEc62tYcHLMtt0qAkNDUVlPFL9D7Q9-73WpwrS3OI_TmLvqy1IMJ4M2_P6PfmHX4aQRlWkhdGrw9Nojhx86lbAafrOt7GF3YJUOl0DVnhO9niQNqY0gpuu40hhKzT8icEipSmENCpez13xZPRb8jKcCbIwCpXLmLMFqf_nCqIYKovVV14O5Dn0te235Xbm42Dvq8-b-HR8ORrdQ</recordid><startdate>201408</startdate><enddate>201408</enddate><creator>Burke, Erin</creator><creator>Dobkin, Bruce H</creator><creator>Noser, Elizabeth A</creator><creator>Enney, Lori A</creator><creator>Cramer, Steven C</creator><general>American Heart Association, Inc</general><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201408</creationdate><title>Predictors and Biomarkers of Treatment Gains in a Clinical Stroke Trial Targeting the Lower Extremity</title><author>Burke, Erin ; Dobkin, Bruce H ; Noser, Elizabeth A ; Enney, Lori A ; Cramer, Steven C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6236-7e5c7b99d25892ddbf08c0a3aa5b542c889a48f0f1d63ae2cd3c84a45a76c9183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular system</topic><topic>Cerebral Cortex - physiopathology</topic><topic>Combined Modality Therapy</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Gait - physiology</topic><topic>Humans</topic><topic>Indoles - therapeutic use</topic><topic>Lower Extremity - physiopathology</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neurology</topic><topic>Paresis - etiology</topic><topic>Paresis - physiopathology</topic><topic>Paresis - rehabilitation</topic><topic>Pharmacology. Drug treatments</topic><topic>Stroke - complications</topic><topic>Stroke - physiopathology</topic><topic>Stroke Rehabilitation</topic><topic>Treatment Outcome</topic><topic>Vascular diseases and vascular malformations of the nervous system</topic><topic>Vasodilator agents. Cerebral vasodilators</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Burke, Erin</creatorcontrib><creatorcontrib>Dobkin, Bruce H</creatorcontrib><creatorcontrib>Noser, Elizabeth A</creatorcontrib><creatorcontrib>Enney, Lori A</creatorcontrib><creatorcontrib>Cramer, Steven C</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Stroke (1970)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Burke, Erin</au><au>Dobkin, Bruce H</au><au>Noser, Elizabeth A</au><au>Enney, Lori A</au><au>Cramer, Steven C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictors and Biomarkers of Treatment Gains in a Clinical Stroke Trial Targeting the Lower Extremity</atitle><jtitle>Stroke (1970)</jtitle><addtitle>Stroke</addtitle><date>2014-08</date><risdate>2014</risdate><volume>45</volume><issue>8</issue><spage>2379</spage><epage>2384</epage><pages>2379-2384</pages><issn>0039-2499</issn><eissn>1524-4628</eissn><coden>SJCCA7</coden><abstract>BACKGROUND AND PURPOSE—Behavioral measures are often used to distinguish subgroups of patients with stroke (eg, to predict treatment gains, stratify clinical trial enrollees, or select rehabilitation therapy). In studies of the upper extremity, measures of brain function using functional magnetic resonance imaging (fMRI) have also been found useful, but this approach has not been examined for the lower extremity. The current study hypothesized that an fMRI-based measure of cortical function would significantly improve prediction of treatment-induced lower extremity behavioral gains. Biomarkers of treatment gains were also explored.
METHODS—Patients with hemiparesis 1 to 12 months after stroke were enrolled in a double-blind, placebo-controlled, randomized clinical trial of ropinirole+physical therapy versus placebo+physical therapy, results of which have previously been reported (NCT00221390). Primary end point was change in gait velocity. Enrollees underwent baseline multimodal assessment that included 19 measures spanning 5 assessment categories (medical history, impairment, disability, brain injury, and brain function), and also underwent reassessment 3 weeks after end of therapy.
RESULTS—In bivariate analysis, 8 baseline measures belonging to 4 categories (medical history, impairment, disability, and brain function) significantly predicted change in gait velocity. Prediction was strongest, however, using a multivariate model containing 2 measures (leg Fugl–Meyer score and fMRI activation volume within ipsilesional foot sensorimotor cortex). Increased activation volume within bilateral foot primary sensorimotor cortex correlated positively with treatment-induced leg motor gains.
CONCLUSIONS—A multimodal model incorporating behavioral and fMRI measures best predicted treatment-induced changes in gait velocity in a clinical trial setting. Results also suggest potential use of fMRI measures as biomarkers of treatment gains.</abstract><cop>Hagerstown, MD</cop><pub>American Heart Association, Inc</pub><pmid>25070961</pmid><doi>10.1161/STROKEAHA.114.005436</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0039-2499 |
ispartof | Stroke (1970), 2014-08, Vol.45 (8), p.2379-2384 |
issn | 0039-2499 1524-4628 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4129459 |
source | MEDLINE; American Heart Association Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete; Alma/SFX Local Collection |
subjects | Adult Aged Biological and medical sciences Cardiovascular system Cerebral Cortex - physiopathology Combined Modality Therapy Double-Blind Method Female Gait - physiology Humans Indoles - therapeutic use Lower Extremity - physiopathology Magnetic Resonance Imaging Male Medical sciences Middle Aged Neurology Paresis - etiology Paresis - physiopathology Paresis - rehabilitation Pharmacology. Drug treatments Stroke - complications Stroke - physiopathology Stroke Rehabilitation Treatment Outcome Vascular diseases and vascular malformations of the nervous system Vasodilator agents. Cerebral vasodilators |
title | Predictors and Biomarkers of Treatment Gains in a Clinical Stroke Trial Targeting the Lower Extremity |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T01%3A19%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictors%20and%20Biomarkers%20of%20Treatment%20Gains%20in%20a%20Clinical%20Stroke%20Trial%20Targeting%20the%20Lower%20Extremity&rft.jtitle=Stroke%20(1970)&rft.au=Burke,%20Erin&rft.date=2014-08&rft.volume=45&rft.issue=8&rft.spage=2379&rft.epage=2384&rft.pages=2379-2384&rft.issn=0039-2499&rft.eissn=1524-4628&rft.coden=SJCCA7&rft_id=info:doi/10.1161/STROKEAHA.114.005436&rft_dat=%3Cproquest_pubme%3E1549632038%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1549632038&rft_id=info:pmid/25070961&rfr_iscdi=true |